Document:

EX-10.19

 Exhibit 10.19 
 PORTOLA PHARMACEUTICALS, INC. 

2013 EMPLOYEE STOCK PURCHASE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS:
JANUARY 30, 2013 
 APPROVED BY THE
STOCKHOLDERS: MARCH 8, 2013 
 1. GENERAL; PURPOSE. 

(a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an
opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees. 
 (b) The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum
efforts for the success of the Company and its Related Corporations. 
 (c) This Plan includes two components: a 423
Component and a Non-423 Component. It is the intention of the Company to have the 423 Component qualify as an Employee Stock Purchase Plan. The provisions of the 423 Component, accordingly, will be construed in a manner that is consistent with the
requirements of Section 423 of the Code. In addition, this Plan authorizes the grant of Purchase Rights under the Non-423 Component that does not meet the requirements of an Employee Stock Purchase Plan because of deviations necessary or
advisable to permit or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside of the United States while complying with applicable foreign laws; such Purchase Rights will be granted pursuant to
rules, procedures or subplans adopted by the Board designed to achieve these objectives for Eligible Employees and the Company and its Related Corporations. Except as otherwise provided herein or determined by the Board, the Non-423 Component will
operate and be administered in the same manner as the 423 Component. In addition, under the 423 Component of the Plan, the Company may make separate Offerings which vary in terms (although not inconsistent with the provisions in the Plan and not
inconsistent with the requirements of an Employee Stock Purchase Plan) and the Company will designate which Designated Company is participating in each separate Offering. 
 (d) If a Participant transfers employment from the Company or any Designated 423 Corporation participating in the 423 Component to a Designated Non-423 Corporation participating in the Non-423
Component, he or she will immediately cease to participate in the 423 Component; however, any Contributions made for the Purchase Period in which such transfer occurs will be transferred to the Non-423 Component, and such Participant will
immediately join the then current Offering under the Non-423 Component upon the same terms and conditions in effect for his or her participation in the Plan, except for such modifications as may be required by applicable law. A Participant who
transfers employment from a Designated 

  
 1 

 
Non-423 Corporation participating in the Non-423 Component to the Company or any Designated 423 Corporation participating in the 423 Component will remain a Participant in the Non-423 Component
until the earlier of (i) the end of the current Offering Period under the Non-423 Component, or (ii) the Offering Date of the first Offering in which he or she participates following such transfer. If a Participant transfers employment to
either a Related Corporation or an Affiliate that is not a Designated Company, he or she shall immediately cease to participate in the on-going Offering and his or her accumulated, unused Contributions will be returned as soon as possible.

 2. ADMINISTRATION. 
 (a) The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 2(c). 

(b) The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan: 

(i) To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical),
including which Designated 423 Corporations and Designated Non-423 Corporations will participate in the 423 Component or the Non-423 Component. 
 (ii) To designate from time to time which Related Corporations of the Company will be eligible to participate in the Plan as Designated 423 Corporations and Designated Non-423 Corporations and
which Affiliates will be eligible to participate in the Plan as Designated Non-423 Corporations and also to designate which Designated Companies will participate in each separate Offering (to the extent the Company makes separate Offerings).

 (iii) To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations
for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective. 

(iv) To settle all controversies regarding the Plan and Purchase Rights granted under the Plan. 

(v) To suspend or terminate the Plan at any time as provided in Section 12. 

(vi) To amend the Plan at any time as provided in Section 12. 

(vii) Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests
of the Company and its Related Corporations and to carry out the intent that the 423 Component be treated as an Employee Stock Purchase Plan. 

  
 2 

 (viii) To adopt such procedures and sub-plans as are necessary or appropriate to
permit or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside the United States. Without limiting the generality of, but consistent with, the foregoing, the Board specifically is authorized to
adopt rules, procedures and subplans, which, for purposes of the Non-423 Component, may be outside the scope of Section 423 of the Code, regarding, without limitation, eligibility to participate in the Plan, handling and making of
Contributions, establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and
handling of share issuances, which may vary according to local requirements. 
 (c) The Board may delegate some or all of
the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been
delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee),
subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any
time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that
may arise in the administration of the Plan. 
 (d) All determinations, interpretations and constructions made by the
Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 
 3.
SHARES OF COMMON STOCK SUBJECT TO THE PLAN. 
 (a) Subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 10,000,000
shares of Common Stock (adjusted to reflect any split of the Common Stock on or before the IPO Date), plus the number of shares that are automatically added on January 1 of each year for a period of up to ten years, commencing on the first
January 1 following the IPO Date, in an amount equal to the lesser of (i) 2% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year, and (ii) 25,000,000 shares of Common Stock
(adjusted to reflect any split of the Common Stock on or before the IPO Date). Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1 increase in the share reserve
for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. 

  
 3 

 (b) If any Purchase Right granted under the Plan terminates without having been
exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan. 
 (c) The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. 

4. GRANT OF PURCHASE RIGHTS; OFFERING. 

(a) The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering on
Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate, and with respect to the 423 Component will comply with the requirement of Section 423(b)(5)
of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by
reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in
Sections 5 through 8, inclusive. 
 (b) If a Participant has more than one Purchase Right outstanding under the Plan,
unless he or she otherwise indicates in forms delivered to the Company: (i) each form will apply to all of his or her Purchase Rights under the Plan; and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase
Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical
exercise prices) will be exercised. 
 (c) The Board will have the discretion to structure an Offering so that if the
Fair Market Value of the shares of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of the shares of Common Stock on the Offering Date, then (i) that Offering
will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. 

5. ELIGIBILITY. 
 (a) Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees of a Related Corporation or an Affiliate.
Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company, a Related Corporation or an Affiliate, as the case may be, for
such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may (unless prohibited by law) provide that
no Employee will be eligible to be granted Purchase 

  
 4 

 
Rights under the Plan unless, on the Offering Date, such Employee’s customary employment with the Company, the Related Corporation or the Affiliate is more than 20 hours per week and more
than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code. 
 (b) The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on or after the day on which such person becomes an Eligible Employee,
receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as
described herein, except that: 
 (i) the date on which such Purchase Right is granted will be the “Offering
Date” of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; 

(ii) the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end
of the original Offering; and 
 (iii) the Board may provide that if such person first becomes an Eligible Employee within
a specified period of time before the end of the Offering, he or she will not receive any Purchase Right under that Offering. 

(c) No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted,
such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation (unless otherwise required by law). For purposes of this Section 5(c), the
rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.

 (d) As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only if
such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of the Company or any Related
Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each
calendar year in which such rights are outstanding at any time. 
 (e) Officers of the Company and any Designated
Company, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by law) provide in an Offering that Employees who are highly compensated
Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate. 

  
 5 

 6. PURCHASE RIGHTS; PURCHASE PRICE.

 (a) On each Offering Date, each Eligible Employee will be granted a Purchase Right under the applicable Offering to
purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board but in either case not exceeding 15%, of such Employee’s eligible earnings (as defined by the
Board in each Offering) during the period that begins on the Offering Date (or such other date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.

 (b) The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that
Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. 
 (c) In
connection with each Offering made under the Plan, the Board may specify (i) a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of
shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If
the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each
Participant’s accumulated Contributions) allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable. 

(d) The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of:

 (i) an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or 

(ii) an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. 

7. PARTICIPATION; WITHDRAWAL; TERMINATION. 

(a) An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and
delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each
Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a
third party or otherwise segregated. If permitted in the Offering, a Participant may begin such Contributions with the first payroll 

  
 6 

 
occurring on or after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions
from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. If required under applicable law or if specifically provided in the
Offering, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check or wire transfer prior to a Purchase Date, in the manner directed by the Company.

 (b) During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to
the Company a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant’s Purchase Right in that Offering will immediately terminate and the Company
will distribute to such Participant all of his or her accumulated but unused Contributions. A Participant’s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but
the Participant will be required to deliver a new enrollment form to participate in future Offerings. 
 (c) Unless
otherwise required by applicable law, Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i) is no longer an Employee of a Designated Company for any reason or for no reason or
(ii) is otherwise no longer eligible to participate. The Company will distribute to such individual all of his or her accumulated but unused Contributions. 
 (d) During a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent
and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section 10. 
 (e)
The Company has no obligation to pay interest on Contributions, unless otherwise required by applicable law. 
 8.
EXERCISE OF PURCHASE RIGHTS. 
 (a) On each Purchase Date,
each Participant’s accumulated Contributions will be applied to the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the
Offering. No fractional shares will be issued unless specifically provided for in the Offering. 
 (b) If any amount of
accumulated Contributions remains in a Participant’s account after the purchase of shares of Common Stock on the final Purchase Date of an Offering and such remaining amount is less than the amount required to purchase one share of Common
Stock, then such remaining amount will be held in such Participant’s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant 

  
 7 

 
withdraws from or is not eligible to participate in such Offering, in which case such amount will be distributed to such Participant after the final Purchase Date, without interest (unless
otherwise required by applicable law). If the amount of Contributions remaining in a Participant’s account after the purchase of shares of Common Stock on the final Purchase Date of an Offering is at least equal to the amount required to
purchase one whole share of Common Stock, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date, without interest (unless otherwise required by
applicable law). 
 (c) No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued
upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable laws. If on a Purchase Date the shares of Common Stock are not so
registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan
is in material compliance, except that the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the
Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest (unless otherwise required under applicable local
law). 
 9. COVENANTS OF THE COMPANY. 

The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the
Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless doing so would be an unreasonable cost to the Company compared to the potential benefit to Eligible Employees which the
Company will determine at its discretion. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of
Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights. 

10. DESIGNATION OF BENEFICIARY. 

(a) The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. 

  
 8 

 (b) If a Participant dies, and in the absence of a valid beneficiary designation, the
Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole
discretion, may deliver such shares of Common Stock and/or Contributions to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may
designate. 
 11. ADJUSTMENTS UPON CHANGES IN COMMON
STOCK; CORPORATE TRANSACTIONS. 
 (a) On a Capitalization Adjustment, the
Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a); (ii) the class(es) and maximum number of securities by which the share reserve is to
increase automatically each year pursuant to Section 3(a); (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights; and (iv) the class(es) and number of
securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. 

(b) On a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or acquiring
corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding
Purchase Rights; or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants’ accumulated
Contributions will be used to purchase shares of Common Stock within ten business days prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. 

12. AMENDMENT, TERMINATION OR SUSPENSION OF THE
PLAN. 
 (a) The Board may amend the Plan at any time in any respect the Board deems necessary or
advisable. However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing
requirements, including any amendment that either (i) materially increases the number of shares of Common Stock available for issuance under the Plan, (ii) materially expands the class of individuals eligible to become Participants and
receive Purchase Rights, (iii) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be purchased under the Plan, (iv) materially extends the term of
the Plan, or (v) expands the types of awards available for issuance under the Plan, but in each of (i) through (v) above only to the extent stockholder approval is required by applicable law or listing requirements. 

  
 9 

 (b) The Board may suspend or terminate the Plan at any time. No Purchase Rights may
be granted under the Plan while the Plan is suspended or after it is terminated. 
 (c) Any benefits, privileges,
entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent
of the person to whom such Purchase Rights were granted, (ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the
regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the Effective Date, or (iii) as
necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right
and/or the Plan complies with the requirements of Section 423 of the Code. 
 13. CODE SECTION 409A;
TAX QUALIFICATION. 
 (a) Purchase Rights granted under the 423 Component are intended
to be exempt from the application of Section 409A of the Code under Treasury Regulation Section 1.409A-1(b)(5)(ii). Purchase Rights granted under the Non-423 Component to U.S. taxpayers are intended to be exempt from the application of
Section 409A of the Code under the short-term deferral exception and any ambiguities will be construed and interpreted in accordance with such intent. Subject to Section 13(b) hereof, Purchase Rights granted to U.S. taxpayers under the
Non-423 Component will be subject to such terms and conditions that will permit such Purchase Rights to satisfy the requirements of the short-term deferral exception available under Section 409A of the Code, including the requirement that the
shares subject to a Purchase Right be delivered within the short-term deferral period. Subject to Section 13(b) hereof, in the case of a Participant who would otherwise be subject to Section 409A of the Code, to the extent the Board
determines that a Purchase Right or the exercise, payment, settlement or deferral thereof is subject to Section 409A of the Code, the Purchase Right will be granted, exercised, paid, settled or deferred in a manner that will comply with
Section 409A of the Code, including U.S. Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the adoption of the
Plan. Notwithstanding the foregoing, the Company will have no liability to a Participant or any other party if the Purchase Right that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for
any action taken by the Board with respect thereto. 
 (b) Although the Company may endeavor to (i) qualify a
Purchase Right for favorable tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii) avoid adverse tax treatment (e.g., under Section 409A of the Code), the Company makes no
representation to that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax treatment, notwithstanding anything to the contrary in this 

  
 10 

 
Plan, including Section 13(a) hereof. The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants under the Plan.

 14. EFFECTIVE DATE OF PLAN. 

The Plan will become effective on the IPO Date. No Purchase Rights will be exercised unless and until the Plan has been approved by the
stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board. 

15. MISCELLANEOUS PROVISIONS. 
 (a) Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. 

(b) A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of
Common Stock subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). 

(c) The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter
the at will nature of a Participant’s employment, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation or an Affiliate, or on
the part of the Company or a Related Corporation or an Affiliate to continue the employment of a Participant. 
 (d) The
provisions of the Plan will be governed by the laws of the State of California without resort to that state’s conflicts of laws rules. 
 (e) If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not affect the other provisions of the Plan, but the Plan will be construed in all
respects as if such invalid provision were omitted. 
 16. DEFINITIONS. 

As used in the Plan, the following definitions will apply to the capitalized terms indicated below: 

(a) “423 Component” means the part of the Plan, which excludes the Non-423 Component, pursuant to which
Purchase Rights that satisfy the requirements for Employee Stock Purchase Plans may be granted to Eligible Employees. 
 (b)
“Affiliate” means any branch or representative office of a Related Corporation, as determined by the Board, whether now or hereafter existing. 

  
 11 

 (c) “Board” means the Board of Directors of the Company.

 (d) “Capitalization Adjustment” means any change that is made in,
or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar
equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment. 
 (e) “Code” means the U.S.
Internal Revenue Code of 1986, as amended. 
 (f) “Committee” means a committee of one or more
members of the Board to whom authority has been delegated by the Board. 
 (g) “Common Stock”
means, as of the IPO Date, the common stock of the Company, having 1 vote per share. 
 (h)
“Company” means Portola Pharmaceuticals, Inc., a Delaware corporation. 
 (i)
“Contributions” means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make
additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions. 

(j) “Corporate Transaction” means the occurrence, in a single transaction or in a series of related
transactions, of any one or more of the following events: 
 (i) the consummation of a sale or other disposition of all or
substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 
 (ii) the consummation of a sale or other disposition of more than 50% of the outstanding securities of the Company; 
 (iii) the consummation of a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or 

(iv) the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation
but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted 

  
 12 

 
or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. 

To the extent required for compliance with Section 409A of the Code, in no event will an event be deemed a Corporate Transaction if
such transaction is not also a “change in the ownership or effective control of” the Company or “a change in the ownership of a substantial portion of the assets of” the Company as determined under Treasury Regulation
Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder). 
 (k) “Designated
Non-423 Corporation” means any Related Corporation or Affiliate selected by the Board as eligible to participate in the Non-423 Component. 
 (l) “Designated Company” means a Designated Non-423 Corporation or Designated 423 Corporation. 

(m) “Designated 423 Corporation” means any Related Corporation selected by the Board as eligible to
participate in the 423 Component. 
 (n) “Director” means a member of the Board. 

(o) “Eligible Employee” means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. 

(p) “Employee” means any person, including an Officer or Director, who is treated as an employee in the
records of the Company or a Related Corporation (including an Affiliate). However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

 (q) “Employee Stock Purchase Plan” means a plan that grants Purchase Rights intended to be
options issued under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Code. 

(r) “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended. 

(s) “Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

 (i) If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair
Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of
determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing sales price on the last preceding date for which such quotation exists. 

  
 13 

 (ii) In the absence of such markets for the Common Stock, the Fair Market Value will
be determined by the Board in good faith in compliance with applicable laws. 
 (iii) Notwithstanding the foregoing, for
any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company’s initial public offering as specified
in the final prospectus for that initial public offering. 
 (t) “IPO Date” means the date of the
underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. 

(u) “Non-423 Component” means the part of the Plan, which excludes the 423 Component, pursuant to which
Purchase Rights that are not intended to satisfy the requirements for Employee Stock Purchase Plans may be granted to Eligible Employees. 
 (v) “Offering” means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more
Purchase Periods. The terms and conditions of an Offering will generally be set forth in the “Offering Document” approved by the Board for that Offering. 

(w) “Offering Date” means a date selected by the Board for an Offering to commence. 

(x) “Officer” means a person who is an officer of the Company or a Related Corporation within the meaning
of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder. 
 (y)
“Participant” means an Eligible Employee who holds an outstanding Purchase Right. 
 (z)
“Plan” means this Portola Pharmaceuticals, Inc. 2013 Employee Stock Purchase Plan, including both the 423 and Non-423 Components, as amended from time to time. 

(aa) “Purchase Date” means one or more dates during an Offering selected by the Board on which Purchase
Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. 

(bb) “Purchase Period” means a period of time specified within an Offering, generally beginning on the
Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. 
 (cc) “Purchase Right” means an option to purchase shares of Common Stock granted pursuant to the Plan. 

  
 14 

 (dd) “Related Corporation” means any “parent
corporation” or “subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. 

(ee) “Securities Act” means the U.S. Securities Act of 1933, as amended. 

(ff) “Trading Day” means any day on which the exchange(s) or market(s) on which shares of Common Stock are
listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. 

  
 15EX-10.20

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.20 
  

			
	SERVICE PROVIDER:	  	 • PPD Development, LP

	SERVICE PROVIDER CONTACT:	  	 • Julia Day

	PORTOLA CONTACT:	  	 • Athiwat Hutchaleelaha / Kevin Romanko

	EFFECTIVE DATE:	  	 • January 2, 2012

  
  

MASTER CONTRACT SERVICES AGREEMENT 
 FOR PRECLINICAL AND CLINICAL SERVICES 
 THIS MASTER CONTRACT SERVICES AGREEMENT
(together with any Work Orders, the “Agreement”) is made as of January 2, 2012 (the “Effective Date”) by and between Portola Pharmaceuticals, Inc., a Delaware corporation with a principal place of
business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080 (Tel: 650-246-7300) (“Portola”) and PPD Development, LP, a Texas Limited Partnership, with a principal office at 929 North Front Street, Wilmington, NC 28401
(Tel: 949-293-1016) (“Service Provider”). 
 1. Background and Agreement Structure. From time to time, Portola may want
Service Provider to provide certain preclinical and clinical research services (the “Services”). Service Provider provides preclinical analytical services and clinical research services for the development of pharmaceutical
products, and acts as a contract research organization to administer human clinical trials and perform pharmacokinetic data management and statistical services in connection with those trials. Portola is sponsoring human clinical trials (each, a
“Study”) of its proprietary compound(s) (each, a “Study Drug”) in accordance with clinical research protocol(s) (each, a “Protocol”). This Agreement contains general terms and conditions
under which Portola would engage Service Provider and under which Service Provider would provide Services. Portola and Service Provider must complete and execute a work order, project order or statement of work, (each, a “Work
Order”) before any Services are provided. For non-clinical services, each Work Order will include, at a minimum, the information relating to the specific Services outlined in the sample Work Order attached as Appendix A. For clinical
services, each Work Order will include, at a minimum, the information relating to the specific Services outlined in the sample Work Order attached as Appendix B. However, neither Portola nor Service Provider is obligated to execute any Work Order.
Once executed, a Work Order becomes part of this Agreement, although the terms in a Work Order will govern only Services described in that Work Order. A Work Order may not change any term in this Agreement unless the Work Order clearly and
specifically states that it is modifying the Agreement and provides reference to the term of this Agreement that is being modified, however, terms may be modified within a Work Order which will be in effect for that specific Work Order and that Work
Order only. 
  

	2.	Services. 

  

	 	2.1	Provision of Services. Service Provider agrees to provide all Services identified in any Work Order: (a) promptly, (b) at such times and at such
places as described in the applicable Work Order, (c) within the time period specified in the applicable Work Order, and (d) in accordance with the highest prevailing industry standards and practices for the performance of similar
services. For each Work Order, Service Provider will designate a “Project Leader” who will be available for frequent communications with Portola regarding the Services provided under that Work Order. For each Work Order, Portola will
designate a “Representative” who will be the point of contact for the Project Leader. 

  

	 	2.2	 Audits. Provided Portola provides reasonable advance notice to Service Provider [*], with [*], Service Provider will allow, at normal business
hours and at mutually agreeable times (a) Portola employees and representatives (representatives may include entities with whom Portola has license 

	 	
agreements or marketing and / or development collaborations to which the Services are related), provided that said representatives who in Service Provider’s discretion, not to be
unreasonably withheld, are not competitors of Service Provider (a competitor meaning an entity that is in the primary business of providing services for which Portola has engaged Service Provider), and (b) representatives of regulatory
agencies, to review Service Provider’s standard operating procedures and records, including financial records, pertaining to the Services and to inspect the facilities used to render the Services under the applicable Work Order. In addition,
the Project Leader and Representative and their designees will participate in meetings to review performance of the Services and to coordinate such Services as necessary. The Representative, or the Representative’s designee, will have access at
reasonable times to observe the Services in progress or review any and all records generated as a result of Service Provider’s performance of the Services. Any Representative designee who is not an employee of Portola shall execute a
confidentiality agreement with Service Provider prior to any such inspection/audit/review. 

  

	 	2.3	Standard Operating Procedures. Service Provider will, upon request, supply copies to Portola of all standard operating procedures of Service Provider relevant to
the Services rendered under a Work Order. 

  

	 	2.4	Regulatory Contacts. Unless otherwise required by applicable law, Portola will be solely responsible for all contacts and communications with any regulatory
authorities with respect to matters relating to any of the Services. Service Provider will notify Portola promptly, and in no event later than one (1) day, after Service Provider receives any contact or communication from any regulatory
authority directly relating in any way to the Services and will provide Portola with copies of any such communication within one (1) day of receipt of such communication by Service Provider. Service Provider will consult with Portola regarding
the response to any inquiry or observation from any regulatory authority relating in any way to the Services and will allow Portola to participate in any further contacts or communications relating to the Services. Service Provider will comply with
all reasonable requests and take into consideration all comments by Portola with respect to all contacts and communications with any regulatory authority relating in any way to the Services. 

 

	 	2.5	Subcontracting. Service Provider may subcontract the performance of certain portions of the Services, with Portola’s prior written consent, which consent
will not be unreasonably withheld, to an Affiliate (defined below) of Service Provider or to a qualified third party; provided, that (a) Service Provider notifies Portola in writing of the Affiliate or proposed subcontractor and identifies the
specific Services to be performed by such Affiliate or subcontractor, (b) such Affiliate or subcontractor performs those Services in a manner consistent with the terms, conditions and obligations of this Agreement, and (c) Service Provider
remains liable for the performance of such Affiliate or subcontractor. Notwithstanding the foregoing, Service Provider will not be liable for the performance of any subcontractor that is required to be used by Portola or any couriers, labeling,
shipping and manufacturing entities. “Affiliate” means, with respect to each party to this Agreement, any corporation, company, partnership, joint venture and/or firm which controls, is controlled by or is under common control with
that party. As used in this Section 2.5, “control” means (i) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of
directors (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction), and (ii) in the case of non-corporate entities, the direct or indirect power to manage, direct or cause the
direction of the management and policies of the non-corporate entity or the power to elect at least fifty percent (50%) of the members of the governing body of such non-corporate entity. 

 

	 	2.6	Change Orders. If the scope of work under a Work Order changes, then the applicable Work Order may be amended as provided in this Section 2.6. If a required
modification to a Work Order is identified by Portola or by Service Provider, the identifying party will notify the other party in writing as soon as reasonably possible. Within fifteen (15) business days of receiving or sending such notice,

  
 [*] = Certain confidential information contained
in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 2 of 22

	 	
Service Provider will provide Portola with a change order containing a description of the required modifications and their effect on the scope, fees and timelines specified in the Work Order,
which change order must be substantially in the form of the sample change order attached hereto as Appendix C (each, a “Change Order”). No Change Order will be effective unless and until it has been signed by an authorized
representative of each party. If Portola does not approve such Change Order, then the parties will use reasonable efforts to agree on a Change Order that is mutually acceptable. If practicable, Service Provider will continue to provide Services
under the existing Work Order during any such negotiations, provided such efforts would facilitate the completion of the work envisioned in the proposed Change Order, but will not commence work in accordance with the Change Order until it is
authorized in writing by Portola. Nothing in this Section 2.6 will limit Portola’s right to terminate the affected Work Order or this Agreement under Section 8. For any Change Order that affects the scope of the regulatory obligations
that have been transferred to Service Provider, Service Provider and Portola will execute a corresponding amendment to the Transfer of Obligations Form. Portola will file such amendment where appropriate, or as required by applicable law or
regulation. 

  

	 	2.7	Portola Cooperation. Portola will cooperate with Service Provider in providing information to Service Provider, taking action and executing documents, as
appropriate, to achieve the objectives of this Agreement. Portola acknowledges and agrees that Service Provider’s performance under this Agreement is dependent on Portola’s timely and effective cooperation with Service Provider.
Accordingly, Portola acknowledges that any delay by Portola may result in Service Provider being released from an obligation or schedule deadline or in Portola having to pay extra fees in order for Service Provider to meet a specific obligation or
deadline despite the delay. Portola shall comply with all applicable laws, rules and regulations governing the performance of its obligations hereunder and the subject matter of this Agreement, including without limitation, the Deliverables (as
defined below). 

  

	 	2.8	Data Verification and Reports. Unless otherwise provided in the applicable Work Order, a copy of all raw data, databases and analytical reports of the data
resulting from the Services will be provided to Portola in a format mutually agreed upon by Portola and Service Provider, compatible with relevant existing databases of Portola and consistent with the Work Order. Service Provider will verify the
accuracy of the data contained in all databases and/or reports provided by it against the raw data and will attach a signed statement attesting to such verification to each database and/or report provided to Portola. 

 

	 	2.9	Transfer or Delegation of Obligations. Service Provider will be responsible for the obligations of a sponsor of a clinical study transferred or delegated by
Portola to Service Provider in Service Provider’s role as the designated contract research organization and as described in a document titled “The Transfer of Obligations of Client Under 21 CFR Subpart D,” (or other applicable
document) which will be included in a Work Order where appropriate. Any transfer of obligations will be construed as a transfer of those obligations described therein in accordance with 21 United States Code of Federal Regulations §312.52 or
other applicable regulation. 

  

	 	2.10	Key Service Provider Personnel. For Services which involve administration and/or monitoring of a Study on behalf of Portola, Service Provider guarantees that the
key Service Provider Personnel (the “Key Service Provider Personnel”) identified and mutually agreed upon in a particular Work Order will remain assigned to the Study covered by such Work Order as long as the individuals remain
employed by Service Provider, unless (a) an individual identified as Key Service Provider Personnel is unavailable for reasons of disability, death, maternity or paternity leave, leave of absence, demotion, illness, promotion or other reasons
not reasonably within Service Provider’s control, or (b) Portola requests, or has requested in connection with an earlier Study, the replacement of any such Key Service Provider Personnel who are not performing to Portola’s
standards. Service Provider will work with Portola in periodically reviewing the performance of the Key Service Provider Personnel and will seek to remedy any underperformance. Service Provider will work with Portola to promptly select a
replacement should any Key Service Provider Personnel resign or become otherwise unavailable as 

  
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

  
 Page 3 of 22

	 	
specified above or should Portola request the replacement of such Key Service Provider Personnel, and Portola will have the right to approve the replacement, which approval will not be
unreasonably withheld. If a change of a Key Service Provider Personnel becomes necessary due to a Key Service Provider Personnel’s unavailability or his or her inability to perform or meet commercially reasonable standards of performance, the
replacement personnel will be adequately trained by Service Provider on the applicable protocol, at Service Provider’s expense, in advance of the replacement, and Service Provider will bear all reasonable costs, including without limitation
costs due to delays caused by the replacement. If a change of a Key Service Provider Personnel is requested by Portola and is not for any of the reasons described in the previous sentence, Portola shall be responsible for Service Provider’s
reasonable costs for training replacement personnel on the applicable Protocol and the parties will mutually agree on a timeline for such replacement. Service Provider shall not be responsible for any delays in meeting Study timelines to the extent
such delays are solely the result of a change in Key Service Provider Personnel requested by Portola in accordance with the foregoing sentence. 

  

	 	2.11	Personnel Retention. If, after Service Provider is authorized to commence Services under a Work Order, such Services are delayed at the request of Portola for
more than [*] and such request for delay is based solely on or results solely from causes which are beyond the control of Service Provider, Service Provider will use commercially reasonable efforts to re-allocate the personnel resources assigned to
the Services during the delay to minimize Portola’s costs of delay. If, however, Portola desires for Service Provider to keep Key Service Provider Personnel assigned to such Services during such delay period, Portola agrees that for the
duration of the delay Portola will pay a fee calculated on an FTE-day basis for each such Key Service Provider Personnel it wishes to remain assigned to the Services. Said personnel fees shall be invoiced by Service Provider on a monthly basis, and
shall be due and payable by Portola within [*] of its receipt of invoice. 

  

	 	2.12	Serious Adverse Event and Medical Management Plan. Notwithstanding anything to the contrary herein, in the event Service Provider and Portola agree upon a
serious adverse event and medical management plan relating to a specific Study (“SMMP”), the parties shall comply with the terms and conditions of any such SMMP. In the event of any conflict between the terms and conditions of the SMMP and
the relevant Work Order, the terms and conditions of the SMMP shall control. Sponsor shall be responsible for any additional costs associated with compliance with the SMMP. 

 

	 	2.13	MedDRA and WHODrug Dictonary License. The parties acknowledge that MedDRA and Uppsala Monitoring Centre product licenses are required by all parties who wish to
distribute or receive MedDRA or WHODrug dictionary terminology. Each party represents and warrants that it possesses a current MedDRA and/or Uppsala Monitoring Centre product license. In the event Portola requests that Service Provider
perform services which require Service Provider to distribute MedDRA terminology or WHODrug dictionary to third parties, Portola shall be responsible for ensuring that all such third parties possess the necessary MedDRA and/or Uppsala Monitoring
Centre product licenses. 

  

	 	2.14	Patient Enrollment. Enrollment numbers are good faith estimates and Service Provider shall exercise all reasonable diligence to meet such enrollment estimates.

  

	 	2.15	Final Protocol. Unless otherwise agreed to in writing by both parties, the parties agree that Portola shall be solely responsible for the final review, approval
and adoption of the Protocol and Service Provider shall not be liable for such Protocol. For clarity, Service Provider shall make commercially reasonable efforts to notify Portola of any errors or inaccuracies of which it becomes aware.

  
 [*] = Certain confidential information contained
in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 4 of 22

	3.	Representations and Warranties by Service Provider. Service Provider makes the following representations and warranties, and agrees to notify Portola in writing
promptly upon any future breach of these representations and warranties: 

  

	 	3.1	Organization of Service Provider. Service Provider is and will remain a legal entity duly organized, validly existing and in good standing under the laws of its
jurisdiction of organization. 

  

	 	3.2	Enforceability of this Agreement. The execution and delivery of this Agreement has been authorized by all requisite action. This Agreement is and will remain a
valid and binding obligation of Service Provider, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors. 

 

	 	3.3	Absence of Other Contractual Restrictions. Service Provider is under no contractual or other obligation or restriction that is inconsistent with Service
Provider’s execution or performance of this Agreement. Service Provider will not enter into any agreement, either written or oral, that would conflict with Service Provider’s responsibilities under this Agreement. 

 

	 	3.4	Qualifications of Service Provider Personnel. Service Provider has, and will, engage employees and approved subcontractors and/or consultants (the
“Service Provider Personnel”) with the proper skill, training and experience to perform the Services. Service Provider will be solely responsible for paying Service Provider Personnel and providing any employee or other benefits
that they are owed. Before providing Services, all Service Provider Personnel must abide by or agree to (a) confidentiality obligations consistent with the terms of this Agreement, and (b) assign or otherwise effectively vest in Service
Provider any and all rights that such personnel might otherwise have in the results of their work. 

  

	 	3.5	Legal Compliance. Service Provider will comply, in all material respects, with all federal and state laws, regulations and orders applicable to its operations,
as well as any other guidelines set forth in the applicable Work Order. 

  

	 	3.6	Conflicts with Rights of Third Parties. To the best of Service Provider’s knowledge, the provision of Services under this Agreement will not violate any
patent, trade secret or other proprietary or intellectual property right of any third party. 

  

	 	3.7	Absence of Debarment. None of Service Provider, its officers, Service Provider Personnel or any other person used by Service Provider to perform Services has
been (a) debarred, convicted, or is subject to a pending debarment or conviction under Subsection (a) or (b) of Section 306 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 335a), (b) named on any of the Food and Drug
Administration’s or any successor entity’s (“FDA”) clinical investigator enforcement lists (including, but not limited to, the (1) Disqualified/Totally Restricted List, (2) Restricted List and (3) Adequate
Assurances List), (c) otherwise listed by any government or regulatory agencies as ineligible to participate in any government healthcare programs or government procurement or non-procurement programs (as that term is defined in 42 U.S.C.
1320a-7b(f)), or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (d) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending
action. Service Provider agrees to inform Portola in writing promptly if Service Provider or any person who is performing Services is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is
pending, or to the best of Service Provider’s knowledge, is threatened. 

  

	4.	Compensation. 

  

	 	4.1	Payment. Portola shall pay Service Provider for all Services performed under a Work Order (“Direct Fees”) in accordance with the rates
for such Services set forth in such Work Order. Portola shall also reimburse Service Provider for all out-of-pocket expenses described in the Work Order or otherwise approved by Portola incurred in connection with the performance of the Services
with respect to a Study, including, without limitation, investigator grants and fees, travel expenses, shipping and postage costs, copying and printing fees, copyright fees, third party drug storage and distribution fees, 

 
 [*] = Certain confidential information contained in this document, marked
by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 5 of 22

	 	
required Institutional Review Board or similar board or committee fees, and other “pass through” expenses reasonably expected to be incurred in connection with performing the Services
(collectively, the “Pass Through Costs”). Except as otherwise expressly provided in a Work Order, Service Provider shall submit to Portola for each Project a monthly invoice describing the Services performed on such Project,
the Direct Fees due for such Services and all Pass Through Costs paid by Service Provider over the past month. Invoices will contain such detail, and will be accompanied by such supporting documentation, as Portola may reasonably require and will be
payable in U.S. Dollars. All undisputed payments will be made by Portola within [*] of its receipt of such an invoice. Portola and Service Provider will attempt in good faith to resolve any disputed invoice amounts and Portola shall pay any amounts
due within [*] of resolution. Service Provider will retain complete and accurate financial records related to all Services performed. Such records will be subject to Portola’s rights under Section 2.2. Service Provider shall have no
obligation to pay subcontractor costs or investigator grant payments to any subcontractor or investigator site (the “Site”) for conduct of services related to a Project until Service Provider has received payment of such Pass
Through Costs from Portola. 

  

	 	4.2	Payments. Unless otherwise set forth in a Work Order, all payments to Service Provider under this Agreement or any Work Order shall be made as follows:

  

			
	If made by check, payment mailed to:	  	PPD Development, LP
		  	12937 Collections Center Drive
		  	Chicago, Illinois 60693
		  	Tax ID# [*]
		
	If made by wire transfer, payment wired to:	  	Bank of America
		  	Acct: [*]
		  	ABA: [*]
		  	Acct Name: PPD Development, LP

 Any changes to the payee information set forth above requires a writing signed by Service Provider’s
treasurer or chief financial officer. 
  

	 	4.3	Foreign Currency Management. If Direct Fees, Pass Through Costs, or investigator payments are to be incurred in any currency other than United States Dollars,
the Services shall be invoiced and paid in accordance with the principles set forth in Appendix D of this Agreement, Foreign Currency Management. 

  

	5.	Proprietary Rights. 

  

	 	5.1	Materials. All biological, chemical and other materials controlled by Portola and furnished to Service Provider by or on behalf of Portola (collectively, the
“Materials”) and all associated intellectual property rights will remain the exclusive property of Portola. Service Provider will use Materials only as necessary to perform the Services and will treat them in accordance with the
requirements of this Section 5.1. Service Provider agrees that it will not use or evaluate Materials or any portions thereof for any other purpose except as directed or permitted in writing by Portola. Without Portola’s prior express
written consent, Service Provider agrees that it will not analyze Materials, or transfer or make Materials available to third parties. 

  

	 	5.2	Deliverables. Service Provider assigns and agrees to assign to Portola all rights in the United States and throughout the world to inventions, discoveries,
improvements, ideas, designs, processes, formulations, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, information, data, documentation, reports, research, creations and other products arising or
resulting from performance of the Services (whether or not patentable or subject to copyright or trade secret protection) (collectively, the “Deliverables”). For purposes of the copyright 

 
 [*] = Certain confidential information contained in this document, marked
by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 6 of 22

	 	
laws of the United States, Deliverables will constitute “works made for hire,” except to the extent such Deliverables cannot by law be “works made for hire.” Portola will have
the right to use Deliverables for any and all purposes. During and for a reasonable period after the term of this Agreement, Service Provider will, and will cause its Affiliates and Service Provider Personnel to, reasonably cooperate in obtaining
patent and other proprietary protection for any patentable Deliverables, all in the name of Portola and at Portola’s cost and expense. Such cooperation will include, without limitation, executing and delivering all requested applications,
assignments and other documents, and taking such other measures as Portola may reasonably request in order to perfect and enforce Portola’s rights in the Deliverables. Notwithstanding the foregoing, Service Provider possesses and will retain
full ownership rights in and to all inventions, processes, technology, know-how, trade secrets, improvements, other intellectual property and assets, including, without limitation, those related to business or product plans or proposals, marketing
strategies, standard operating procedures, data, composition of matter, research, experimental results, personnel data, financial information and conditions, pricing information, customer information, supplier/vendor information, raw materials, data
collection and data management processes, laboratory analyses, analytical, biotechnology and clinical methods, procedures and techniques, computer technical expertise and software (including code), templates, programs and other materials developed
or obtained or licensed from third parties by Service Provider and its Affiliates prior to or independent of the performance of its obligations under this Agreement, including all improvements and enhancements thereto made by Service Provider or its
Affiliates that do not incorporate or reference any Confidential Information of Portola (“Service Provider Property”), regardless of whether such Service Provider Property is used in connection with Service Provider’s
performance of the Services. Provided that in no event shall Service Provider Property be disclosed or assigned by Portola to a competitor of Service Provider as defined in Section 2.2, except where (i) Service Provider integrates Service
Provider Property as part of the Deliverable, (ii) is required for the further commercialization of Portola’s property, e.g., it cannot be removed or protected, and (iii) proper safeguards from the competitor regarding future non-use
are in place, except for purposes of the follow-on service, Service Provider hereby grants to Portola a perpetual, non-exclusive, fully paid-up, assignable, worldwide license to use Service Provider Property, [*] of Service Provider, that is
incorporated into or is otherwise required to use the Deliverables, solely to the extent necessary for Portola’s or Portola’s assignee’s reasonable use of the Deliverables or as necessary to obtain the benefit of the Deliverables and
Services provided by Service Provider. 

  

	 	5.3	Work at Third Party Facilities. Service Provider will not use any third party facilities, materials or intellectual property in performing the Services without
Portola’s prior written consent. 

  

	 	5.4	Records; Records Storage. Service Provider will maintain all materials (including, but not limited to, Materials) and all data and documentation obtained or
generated by Service Provider in the course of preparing for or providing Services hereunder, including all computerized records and files (collectively, the “Records”) in a secure area reasonably protected from fire, theft and
destruction. For purposes of the copyright laws of the United States, these Records will be “works made for hire” and will remain the exclusive property of Portola. 

 

	 	5.5	Record Retention. All Records will be retained by Service Provider for a period of [*], or such longer period as required under applicable law or regulation
(“Record Retention Period”). At the end of the Record Retention Period, such Records will, at Portola’s option, be (i) delivered to Portola [*] to its offices identified herein in such form as is then currently in the
possession of Service Provider, (ii) disposed of [*], as directed by written request of Portola, unless the Records are otherwise required to be stored or maintained by Service Provider under applicable law. If Service Provider is required or
requested to maintain and/or store the Records for a period beyond [*] after the termination or expiration of the Services, Portola shall reimburse Service Provider for its maintenance and storage costs. In no event shall Service Provider dispose of
Records without first giving Portola sixty (60) days prior written notice of its intent to dispose of the Records. Service Provider may retain copies of any Records as are reasonably necessary for regulatory or insurance purposes, subject to
Service Provider’s obligations of confidentiality under this Agreement. 

  
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

  
 Page 7 of 22

	6.	Confidential Information. 

  

	 	6.1	Definition. “Portola Confidential Information” means all scientific, technical, financial or business information or materials owned, possessed
or used by Portola, that is learned of by Service Provider or developed by Service Provider in connection with the Services, whether or not labeled “Confidential”, including but not limited to (a) Materials, Deliverables, scientific
and medical data, investigator brochures, and protocols, (b) development and marketing plans, regulatory and business strategies, financial information, and forecasts of Portola, and (c) all information of third parties that Portola has an
obligation to keep confidential. 

  

	 	6.2	Definition. “Service Provider Confidential Information” means all information obtained from Service Provider or any of Service Provider’s
Affiliates, including, without limitation, any Service Provider bids or proposals, standard operating procedures, personnel information, all Service Provider Property (as defined above) and any revisions, improvements or enhancements thereto. In
addition, any affiliate of Portola receiving information from Service Provider or Service Provider Affiliate shall be bound by these confidentiality obligations. Further, any information disclosed, obtained, or observed by Portola during an audit of
Service Provider or an Affiliate of Service Provider, or the facilities of either, with the exception of Portola Confidential Information, shall be treated as confidential by Portola in accordance with the terms contained herein.

  

	 	6.3	Obligations of Confidentiality. During the term of this Agreement and for a period of [*] thereafter, except as otherwise expressly provided in this Agreement,
neither party shall directly or indirectly, publish, disseminate or otherwise disclose, or deliver or make available to any third party, or use any Confidential Information, of the other party other than in furtherance of the purposes of this
Agreement, and only then with the prior written consent of said party. Each party will exercise all reasonable precautions to protect the integrity and confidentiality of the other party’s Confidential Information. Each party may disseminate or
permit access to the other party’s Confidential Information only to those who have a need to know such Confidential Information in the course of the performance of their duties under this Agreement and who are bound to obligations of
confidentiality and non-use of the Confidential Information that are at least as restrictive as those set forth in this Agreement. 

  

	 	6.4	Exceptions. Neither party will have obligations of non-disclosure and non-use with respect to any portion of the Confidential Information of the other party
which: 

  

	 	(a)	is or later becomes generally available to the public by use, publication or the like, through no fault of the receiving party; 

 

	 	(b)	is obtained from a third party who had the legal right to disclose such Confidential Information to the receiving party without obligation of confidentiality;

  

	 	(c)	is in the receiving party’s prior possession without obligation of confidentiality, as evidenced by Service Provider’s written records; or

  

	 	(d)	is independently developed by the receiving party without the use or or reliance upon the Confidential Information of the other party. 

 

	 	6.5	Disclosure Required by Law. In the event that a party is required by order of a court or other government entity having jurisdiction to disclose any Confidential
Information of the other party, said party will give the other party prompt notice thereof so that the disclosing party may seek an 

  

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to
Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 8 of 22

	 	
appropriate protective order. The receiving party will reasonably cooperate with the disclosing party in its efforts to seek such a protective order. In the event that disclosure is required, the
receiving party shall disclose only that portion of such Confidential Information that it is legally required to disclose. 

  

	 	6.6	Return of Information. Upon termination or expiration of this Agreement or at the disclosing party’s earlier written request, the receiving party shall
return, and shall cause its agents to return, all documentary, electronic or other tangible forms of Confidential Information provided by the disclosing party including, without limitation, any and all copies thereof, or, at the disclosing
party’s request, destroy all or such parts of the disclosing party’s Confidential Information as the disclosing party shall direct. Notwithstanding the foregoing, the receiving party may retain copies of such of the disclosing party’s
Confidential Information as is reasonably necessary for regulatory and business archival purposes, subject to the ongoing obligation to maintain the confidentiality of such information. 

 

	7.	Data Privacy. 

  

	 	7.1	Definitions. For the purpose of this Section 7, ‘Personal Data’, ‘Process/Processing’, ‘Data Controller’, ‘Data
Processor’ and ‘Data Subject’ shall have the same meaning as in Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data
and on the free movement of such data (“Directive 95/46/EC”) as implemented in the law of any EU Member State which is applicable to the provision of the Services or as defined in the law of any other country which is applicable to the
provision of the Services (including, as applicable, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules, 45 C.F.R. Partis 160-164, and the Health Information Technology for Economic and Clinical Health
Act (HITECH), P.L. No. 111-005, Part I, Title XIII, Subpart D, 13401-13409, and state privacy laws) (collectively referred to as the “Applicable Data Privacy Laws”). 

 

	 	7.2	Compliance. Each party warrants to the other that it will Process the Personal Data in compliance with all Applicable Data Privacy Laws.

  

	 	7.3	Data Processing. Portola and Service Provider acknowledge that Portola is the Data Controller and Service Provider is the Data Processor with respect to the
Processing of Personal Data relating to the Services provided under this Agreement. In the event that the Services are performed by any Service Provider Affiliate then such Service Provider Affiliate shall be a sub-Processor. Service Provider shall
Process the Personal Data only in accordance with instructions from Portola or as may be required or permitted by law. (The instructions may be specific instructions or instructions of a general nature as set out in this Agreement, a Project
Addendum, Protocol, SOP or SMMP or as otherwise notified by Portola to Service Provider during the Term). 

  

	 	7.4	Representative. If Portola wishes to appoint Service Provider as representative to comply with Applicable Data Privacy Law in any EU Member State pursuant to
Article 4 of Directive 95/46/EC and Service Provider is willing to provide such services to Portola, Portola and Service Provider shall enter into a mutually acceptable agreement for such representative purposes. Unless and until such an agreement
is entered into, Service Provider shall not be deemed to be a representative under any Applicable Data Privacy Law. 

  

	 	7.5	Security. Service Provider shall implement appropriate technical and organisational measures to protect the Personal Data as required by ICH-GCP and Applicable
Data Privacy Laws. 

  

	 	7.6	Data Privacy Requests. Service Provider shall promptly notify Portola in writing if it receives any communication with regard to data privacy relating to the
Services from a Data Subject, a privacy 

  
 [*] =
Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 9 of 22

	 	
authority or other regulatory authority, and provide Portola with cooperation and assistance in relation to any such communication. Service Provider shall be entitled to charge Portola for such
assistance, at its usual hourly rate, unless the communication relates to a breach or violation by Service Provider or a Service Provider Affiliate of its obligations under this Section 7. However, Service Provider and Portola recognize that
any fees charged to the requesting party must comply with Applicable Data Privacy Laws. 

  

	 	7.7	Security Breaches. If Service Provider becomes aware of any breach of an Applicable Data Privacy Law relating to the Services, then it shall promptly notify
Portola and, if requested, assist Portola in meeting any obligations under Applicable Data Privacy Law to notify Data Subjects, regulatory authorities or other required parties. Service Provider shall be entitled to charge Portola for such
assistance, at its usual hourly rate, unless Service Provider or a Service Provider Affiliate was solely responsible for such breach. 

  

	 	7.8	Data Transfers. Service Provider shall only Process or otherwise transfer Personal Data outside the European Economic Area (member states of the European Union
plus, Norway, Iceland & Liechtenstein) as set out in this Agreement, any Work Order, Protocol, SOP or SMMP or with the prior consent of Portola. 

  

	8.	Indemnification, Insurance and Liability. 

  

	 	8.1	Indemnification by Service Provider. Service Provider agrees to indemnify Portola and its directors, officers, and employees (collectively, the “Portola
Indemnitees”) from and against any and all liability, loss, damage, cost, and expense, including reasonable attorneys’ fees and costs (collectively, “Losses”) they may suffer in connection with any claim or lawsuit
brought by a third party arising from a Service Provider Indemnitee’s (defined below) or Service Provider’s approved subcontractors’ (a) negligence or willful misconduct, or (b) material breach of this Agreement.
Notwithstanding the foregoing, Service Provider’s obligation to indemnify the Portola Indemnitees will be proportionally reduced to the extent that such Losses fall within Portola’s indemnification obligations under Section 8.2 below.

  

	 	8.2	Indemnification by Portola. Portola agrees to indemnify Service Provider and its directors, officers, and employees (collectively, the “Service Provider
Indemnitees”) from and against any and all Losses they may suffer in connection with any claim or lawsuit brought by a third party arising from (a) personal injury, or death of a Study subject caused by (i) any Study Drug or other
materials supplied by Portola or anyone acting on Portola’s behalf that is dispensed in strict accordance with the relevant Protocol and Portola’s written instructions, (ii) any non-standard of care procedure required by the Protocol,
(b) any deviations from the applicable Protocol necessary to preserve the health, safety and welfare of the Study subjects that meets all applicable standards of care, (c) any claims for patent infringement related to a Study Drug,
compound or other materials supplied by Portola, or anyone acting on Portola’s behalf, to Service Provider in connection with a Study, provided Service Provider Indemnitee has acted in strict compliance with the relevant Protocol and
Portola’s instructions, (d) after regulatory approval of a Study Drug that was the subject of the Services, personal injury or death caused by such Study Drug, or (e) a Portola Indemnitees’ use of the Deliverables, negligence,
willful misconduct, or material breach of this Agreement. Notwithstanding the foregoing, Portola’s obligation to indemnify the Service Provider Indemnitees will be proportionally reduced to the extent that such Losses fall within Service
Provider’s indemnification obligations under Section 8.1 above. 

  

	 	8.3	Indemnification Procedures. Each party agrees to notify the other party within fifteen (15) days of receipt of any claims made for which the other party
might be liable under Section 8.1 or 8.2, as the case may be. The indemnifying party will have the right, but not the obligation, to defend, negotiate, and settle such claims. The indemnified party will be entitled to participate in the

  
 [*] = Certain confidential information contained
in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 10 of 22

	 	
defense of such matter and to employ counsel at its expense to assist therein; provided, however, that if the indemnifying party elects to defend the indemnified party, the indemnifying
party will have final decision-making authority regarding all aspects of the defense of any claim. The party seeking indemnification will provide the indemnifying party with such information and assistance as the indemnifying party may reasonably
request, at the expense of the indemnifying party. Neither party will be responsible or bound by any settlement of any claim or suit made without its prior written consent; provided, however, that the indemnified party will not
unreasonably withhold or delay such consent. If a settlement contains an absolute waiver of liability for the indemnified party, and each party has acted in compliance with the requirements of this Section 8.3, then the indemnified party’s
consent will be deemed given. Notwithstanding the foregoing, neither party will agree to settle any claim on such terms or conditions as would impair the other party’s ability or right to research, develop, manufacture, market, sell or
otherwise use the Study Drug, or as would impair a party’s ability, right or obligation to perform its obligations under this Agreement. 

  

	 	8.4	Insurance. Portola and Service Provider will each undertake to purchase and maintain insurance of such types and amounts reasonably adequate to cover any
liabilities arising out of its obligations hereunder. Portola further undertakes to purchase and maintain insurance of such types and amounts reasonably adequate (including but not limited to that required by law) to cover any
liabilities arising in relation to all clinical trials contracted to Service Provider pursuant to this Agreement. 

 Portola and Service Provider will each undertake, upon request by the other party, to provide the other party a certificate (or certificates) of insurance setting forth the liability limits,
exclusions and deductibles of the insurance such party is required to carry pursuant to this Agreement. 
  

	 	8.5	Liability. 

  

	 	(a)	For Failure to Perform. In the event that the Services provided hereunder (or any portion thereof) do not meet the specifications or other performance criteria
agreed to by Service Provider and Portola in a Work Order, then Service Provider will, at Portola’s first option, promptly (i) re-perform such Services at Service Provider’s cost, or (ii) refund to Portola all amounts paid by
Portola to Service Provider in connection with such Services. 

  

	 	(b)	Limitation. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR
PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN SECTION 6. NOTHING IN THIS SECTION 8.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. TO
THE FULLEST EXTENT PERMITTED BY LAW, AND NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT OR ANY WORK ORDER, THE TOTAL LIABILITY, IN THE AGGREGATE, OF [*] AND ITS AGENTS, AND ANY OF THEM, TO [*] AND ANYONE CLAIMING BY OR THROUGH [*], FOR ANY
AND ALL CLAIMS, LOSSES, COSTS OR DAMAGES, INCLUDING WITHOUT LIMITATION, ATTORNEYS’ FEES AND COSTS AND EXPERT-WITNESS FEES AND COSTS OF ANY NATURE WHATSOEVER OR CLAIMS EXPENSES RESULTING FROM OR IN ANY WAY RELATED TO THIS AGREEMENT OR ANY WORK
ORDER FROM ANY CAUSE OR CAUSES SHALL NOT EXCEED [*] OR [*] THE [*] OR [*], WHICH IS OR ARE [*]. IT IS INTENDED THAT THIS LIMITATION APPLY TO ANY AND ALL LIABILITY OR CAUSE OF ACTION HOWEVER ALLEGED OR ARISING EXCEPT FOR THE PARTIES’ INDEMNITY
OBLIGATIONS UNDER SECTIONS 8.1 AND 8.2.  

  
 [*]
= Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 11 of 22

	 	8.6	Each party agrees that its obligations hereunder are necessary and reasonable in order to protect the other party and the other party’s business, and
expressly agrees that monetary damages would be inadequate to compensate the other party for any breach of the terms of this Agreement. Accordingly, each party agrees and acknowledges that any such violation or threatened violation may cause
irreparable injury to the other party, and that, in addition to any other remedies that may be available, in law, in equity or otherwise, the other party shall be entitled to obtain injunctive relief against the threatened breach of this Agreement
or a Work Order or the continuation of any such breach, without the necessity of proving actual damages. 

  

	9.	Expiration and Termination. 

  

	 	9.1	Expiration. This Agreement will expire on the later of (a) three (3) years from the Effective Date or (b) the completion of all Services under the
last Work Order executed by the parties prior to the second anniversary of the Effective Date. This Agreement may be extended by mutual agreement of the parties or earlier terminated in accordance with Sections 9.2 or 9.3 below.

  

	 	9.2	Termination by Portola. Portola may immediately terminate this Agreement at any time upon written notice to Service Provider in the event of a material breach of
this Agreement or any Work Order by Service Provider which cannot be cured (e.g., a breach of the confidentiality obligations). Further, Portola may terminate this Agreement or any Work Order at any time upon thirty (30) days prior written
notice to Service Provider. 

  

	 	9.3	Termination by Service Provider. Service Provider may immediately terminate this Agreement at any time upon written notice to Portola in the event of a material
breach of this Agreement or any Work Order by Portola which cannot be cured (e.g., a breach of the confidentiality obligations). Further, Service Provider may terminate this Agreement or any Work Order upon thirty (30) days prior written
notice to Portola if Portola breaches this Agreement or any Work Order and fails to cure the breach during the relevant notice period. 

  

	 	9.4	Insolvency. Either party hereto may terminate this Agreement immediately upon the occurrence of an “Insolvency Event” with respect to the other party.
For purposes of this Agreement, “Insolvency Event” shall mean (1) a party or any of its subsidiaries commences a voluntary proceeding seeking liquidation, reorganization or other relief with respect to itself or its
debts under any bankruptcy, insolvency or other similar law or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, or consents to any such relief or to the
appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or makes a general assignment for the benefit of creditors, or fails generally to pay its debts as they become due, or takes
any action to authorize any of the foregoing; (2) an involuntary case or other proceeding shall be commenced against a party or any of its subsidiaries seeking liquidation, reorganization or other relief with respect to it or its debts under
bankruptcy, insolvency or other similar law or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such involuntary case or other proceeding shall remain
undismissed and unstayed for a period of [*]; or (3) an order for relief shall be entered against a party or any of its subsidiaries under the federal bankruptcy laws now or hereafter in effect. 

 

	 	9.5	Effect of Termination or Expiration. Upon termination or expiration of this Agreement, neither Service Provider nor Portola will have any further obligations
under this Agreement, or in the case of termination or expiration of a Work Order, under that Work Order, except that: 

  

	 	(a)	Service Provider will terminate all Services in progress in an orderly manner as soon as practicable and in accordance with a schedule agreed to by Portola, unless
Portola specifies in the notice of termination that Services in progress should be completed; 

  
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

  
 Page 12 of 22

	 	(b)	Service Provider will deliver to Portola or, at Portola’s option, dispose of, any Materials in its possession or control and all Deliverables developed through
termination or expiration; 

  

	 	(c)	Portola will pay Service Provider any monies due and owing Service Provider, up to the time of termination or expiration, for Services performed in accordance with an
applicable Work Order and all authorized expenses and irrevocable, non-mitigable, and noncancelable commitments actually incurred (as specified in the applicable Work Order); 

 

	 	(d)	Service Provider will refund any monies paid in advance by Portola for Services not rendered within [*] after the termination date of the Work Order or this Agreement,
whichever is applicable; 

  

	 	(e)	Each party will promptly return to the other all copies of all Confidential Information of the other party in its possession or control that relate to this Agreement
or, if this entire Agreement has not expired or been terminated, under any Work Order which has been terminated or has expired, except for one (1) copy which each party may retain solely to monitor its surviving obligations of confidentiality;
and 

  

	 	(f)	The terms, conditions and obligations under Sections 2.2, 2.4, 4, 5, 6, 8, 9.5, 10.2, 10.3, 10.4, 10.7, 10.8, 10.9, and 10.15 will survive any such termination or
expiration. 

  

	10.	Miscellaneous. 

  

	 	10.1	Independent Contractor. All Services will be rendered by Service Provider as an independent contractor and this Agreement does not create an employment
relationship, partnership or joint venture between Portola and Service Provider. Neither party will in any way represent itself to be a partner or joint venturer of or with the other party. 

 

	 	10.2	Use of Names. Neither party has the right to use the other party’s name, symbol, trade name or the names of the other party’s employees in any
advertising, sales promotional material or press release without prior written permission of the other party, in each instance, except to the extent such disclosure is reasonably necessary for (a) regulatory filings, including filings with the
U.S. Securities Exchange Commission or FDA, (b) prosecuting or defending litigation, and (c) complying with (i) applicable governmental regulations and legal requirements and (ii) the requirements of any stock exchange or stock
listing entity. 

  

	 	10.3	Notices. All notices required or permitted under this Agreement must be in writing and must be given by addressing the notice to the address for the recipient
set forth in this Agreement or at such other address as the recipient may specify in writing under this procedure. Notices to Portola will be marked “Attention: Mardi Dier, Chief Financial Officer”. Notices to Service Provider will be
marked “Attention: General Counsel”. Notices will be deemed to have been given (a) three (3) business days after deposit in the mail with proper postage for first class registered or certified mail prepaid, or (b) one
(1) business day after sending by nationally recognized overnight delivery service 

  

	 	10.4	Assignment. This Agreement may not be assigned or transferred, in whole or in part, by either party without the prior written consent of the other party;
provided, however, that (i) a party hereto may assign this Agreement or a Work Order hereunder to a successor-in-interest to the party’s business and (ii) Service Provider may assign this Agreement or a Work Order or subcontract all
or part of the Services to be performed hereunder to Service Provider Affiliates, provided Service Provider remains liable for performance of the Services. In the event the Services shall be performed by a Service Provider Affiliate, such Service
Provider Affiliate may be the contracting party to any Project Addendum for the Services. 

  
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

  
 Page 13 of 22

	 	10.5	Entire Agreement. This Agreement constitutes the entire agreement of the parties with regard to its subject matter, and supersedes all previous written or oral
representations, agreements and understandings between Portola and Service Provider with regard to such subject matter, including without limitation a Mutual Confidentiality Agreement dated April 30, 2010 and a Letter of Intent dated
January 13, 2012 (the “LOI”). Upon execution of this Agreement, Services (as defined in the LOI) performed under the LOI shall be subject to the terms of this Agreement. In the event of any conflict, discrepancy, or inconsistency
between the terms set forth in the body of this Agreement, any Work Order or any purchase order issued under this Agreement, the terms of the body of this Agreement will control unless specifically stated otherwise in a Work Order. Further, the
terms of a Work Order will control over the terms of any purchase order issued by Portola for the Services under that Work Order. 

  

	 	10.6	No Modification. This Agreement may be changed only by a writing signed by an authorized representative of each party. 

 

	 	10.7	Severability; Reformation. Any of the provisions of this Agreement which are determined to be invalid or unenforceable in any jurisdiction will be
ineffective to the extent of such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable the remaining provisions hereof and without affecting the validity or enforceability of any of the other terms of this
Agreement in such jurisdiction, or the terms of this Agreement in any other jurisdiction. The parties will substitute for the invalid or unenforceable provision a valid and enforceable provision that conforms as nearly as possible with the original
intent of the parties. 

  

	 	10.8	Governing Law. This Agreement will be construed and interpreted and its performance governed by the laws of the State of New York, without regard to any choice
of law principle that would dictate the application of the law of another jurisdiction. The parties expressly reject any application to this Agreement of (a) the United Nations Convention on Contracts for the International Sale of Goods, and
(b) the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol adopted in Vienna on April 11, 1980. 

 

	 	10.9	Waiver. No waiver of any term, provision or condition of this Agreement in any one or more instances will be deemed to be or construed as a further or continuing
waiver of any other term, provision or condition of this Agreement. Any such waiver must be evidenced by an instrument in writing executed by an officer authorized to execute waivers. 

 

	 	10.10	Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original and all of which together will constitute
one and the same instrument. A facsimile or scanned copy of this Agreement that includes a party’s signature will be deemed an original. 

  

	 	10.11	Headings. This Agreement contains headings only for convenience and such headings should not be used in the construction of this Agreement.

  

	 	10.12	Force Majeure. If either party shall be delayed, hindered, or prevented from the performance of any act required hereunder by reason of strike, lockouts, labor
troubles, restrictive governmental or judicial orders or decrees, riots, insurrection, war, acts of God, inclement weather, or other cause beyond such party’s reasonable control (each, a “Disability”), then performance
of such act shall be excused for the length of time necessary to cure such Disability and resume performance. A party shall not be liable for any delays resulting from a Disability, and any affected timelines shall be extended for a period at least
equal to that of the Disability. The party incurring the Disability shall provide notice to the other of the commencement and termination of the Disability. 

 
 [*] = Certain confidential information contained in this document, marked
by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 14 of 22

	 	10.13	Construction. Except where the context otherwise requires, wherever used the singular shall include the plural, the plural the singular, the use of any gender
shall be applicable to all genders and the word “or” is used in the inclusive sense. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement
or the intent of any provision contained in this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the parties and no rule of strict construction shall be applied against either party hereto.

  

	 	10.14	Representative. With regard to any Project conducted under this Agreement, Portola represents and warrants that it shall not name any Service Provider employee
or other Service Provider representative on Line 15 of Form FDA 1571 or as the Senior Medical Officer in Canada on Line 87 of Form HC/SC 3011 or in any similar capacity for clinical trials conducted in other countries without Service Provider’s
written consent. Portola acknowledges and understands that if Portola desires Service Provider to be responsible for review and evaluation of information relevant to the safety of the drug, Portola will have to enter into a separate contract with
Service Provider for the provision of these services. 

  

	 	10.15	Covenant Not to Interfere. Neither party will hire for employment any employee of the other party involved in providing or receiving Services under a Work Order
while the employee is still employed by the other party during the active term of the Work Order. 

 IN WITNESS
WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date. 
  

									
	PORTOLA PHARMACEUTICALS, INC.	 		 	PPD DEVELOPMENT, LP
		 		 		 	By:    PPD GP, LLC
		 		 		 	Its:    General Partner
					
	By:	 	 /s/ Mardi C. Dier
	 		 	By: 	 	 /s/ William J. Sharbaugh

					
	Print Name:	 	 Mardi C. Dier
	 		 	Print Name:	 	 William J. Sharbaugh

					
	Title:	 	 Chief Financial Officer
	 		 	Title:	 	 Chief Operating Officer

					
	Date:	 	 February 1, 2012
	 		 	Date:	 	 2 February 2012

  
 [*] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 15 of 22

			
	SERVICE PROVIDER:	  	 • [*]

	PORTOLA CONTACT:	  	 • [*]

	MCSA EFFECTIVE DATE:	  	 • [*]

	PORTOLA PROJECT / TASK CODE:	  	 • [*]

  
  

APPENDIX A 

SAMPLE WORK ORDER NO.     
 THIS WORK ORDER NO.     (the “Work Order”) is by and between Portola Pharmaceuticals, Inc. (“Portola”) and [*] (the “Service
Provider”), and upon execution will be incorporated into the Master Contract Services Agreement between Portola and Service Provider dated [*] (the “Agreement”). Capitalized terms in this Work Order will have the
same meaning as set forth in the Agreement. Portola hereby engages Service Provider to provide Services, as follows: 
  

	 	1.	Services. Service Provider will render to Portola the following Services: 

 Describe specific Service to be provided including all Deliverables (or attach work proposal); if applicable, specify GLP. 
 All Deliverables will be provided to Portola in a mutually agreeable format. The parties agree that any terms contained in any proposal which is attached to this Work Order are binding and to the extent
the terms of any such proposal conflict with the terms of the Agreement or this Work Order, the terms of the Agreement and the Work Order will prevail, in that order. 
  

	 	2.	Materials. Portola will provide to Service Provider the following Materials for the Services: 

Describe specific materials being provided by Portola. 

 

	 	3.	Completion. The Services will be completed within [*]. 

  

	 	4.	Service Provider Project Leader/Portola Representative. [*] and [*] 

 

	 	5.	Compensation. The total compensation due Service Provider for Services is [*]. Such compensation will be paid [*]. Portola and Service Provider must agree
in advance of either party making any change in compensation. 

 The terms of Section 4 (Compensation) of the
Agreement will apply to the compensation due hereunder. 
  

	 	6.	Term and Termination. The term of this Work Order will commence as of the last date of signature below and will continue until completion of the Services
described herein, provided, however, that either party may terminate this Work Order in accordance with Section 9 (Expiration and Termination) of the Agreement. 

 The terms of the Agreement will take precedence and control over the terms of this Work Order and those of any purchase order issued by Portola in connection with these Services; further, the terms of
this Work Order will take precedence and control over those of any purchase order issue by Portola in connection with these Services. All terms and conditions of the Agreement will apply to this Work Order. [*] 

 
 [*] = Certain confidential information contained in this document, marked
by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 16 of 22

									
	WORK ORDER AGREED TO AND ACCEPTED BY:	 		 		 	
			
	PORTOLA PHARMACEUTICALS, INC.	 		 	[*]
					
	By	 	  
	 		 	By	 	  

					
	Print Name	 	  
	 		 	Print Name	 	  

					
	Title	 	  
	 		 	Title	 	  

		 	duly authorized	 		 		 	duly authorized
					
	Date	 	  
	 		 	Date	 	  

  
 [*] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 17 of 22

			
	SERVICE PROVIDER:	  	 • [*]

	PORTOLA CONTACT:	  	 • [*]

	MCSA EFFECTIVE DATE:	  	 • [*]

	PORTOLA PROJECT / TASK CODE:	  	 • [*]

  
  

APPENDIX B 

SAMPLE CLINICAL WORK ORDER NO. [*] 
 THIS WORK ORDER NO. [*] (together with its Appendices, the “Work Order”) is by and between Portola Pharmaceuticals, Inc. (“Portola”) and [*] (the
“Service Provider”), and upon execution will be incorporated into the Master Contract Services Agreement between Portola and Service Provider dated [*] (the “Agreement”). Capitalized terms in this Work Order
will have the same meaning as set forth in the Agreement. Portola hereby engages Service Provider to provide Services, as follows: 
 1. Project Specifications. Service Provider will perform the Services described in Appendix A attached hereto (the “Project Specifications”), in accordance with the schedule
attached hereto as Appendix B (the “Project Schedule”) and any other documents attached to this Work Order (collectively the “Services”). The parties agree that any terms contained in any proposal which is
attached to this Work Order are binding and to the extent the terms of any such proposal conflict with the terms of the Agreement or this Work Order, the terms of the Agreement and the Work Order will prevail, in that order. 

2. Compensation. For performance of these Services, Portola will pay to Service Provider the amounts described in the
Budget and Payment Schedule set forth in Appendix C attached hereto. The terms of Section 4 (Compensation) of the Agreement will apply to the compensation due hereunder. 

3. Term and Termination. The term of this Work Order will commence as of the last date of signature below and will continue until
completion of the Services described in Appendix A, provided, however, that either Party may terminate this Work Order in accordance with Section 9 (Expiration and Termination) of the Agreement. 

4. Designated Contact Persons and Key Service Provider Personnel. The Portola representatives and Key Service Provider Personnel
who will oversee the Services in accordance with the Agreement are identified in Appendix D attached hereto, Designated Contact Persons and Key Service Provider Personnel. 
 5. Incorporation; Conflict. All terms and conditions of the Agreement will apply to this Work Order. The terms of the Agreement will take precedence and control over the terms of this Work Order
and those of any purchase order issued by Portola in connection with these Services; further, the terms of this Work Order will take precedence and control over those of any purchase order issue by Portola in connection with these Services.
[*] 
  

									
	WORK ORDER AGREED TO AND ACCEPTED BY:	 		 		 	
			
	PORTOLA PHARMACEUTICALS, INC.	 		 	[*]
					
	By	 	  
	 		 	By	 	  

					
	Print Name	 	  
	 		 	Print Name	 	  

					
	Title	 	  
	 		 	Title	 	  

		 	duly authorized	 		 		 	duly authorized
					
	Date	 	  
	 		 	Date	 	  

  
 [*] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 18 of 22

 List of Appendices 
  

			
	Appendix A:	  	Project Specifications
	Appendix B:	  	Project Schedule
	Appendix C:	  	Budget and Payment Schedule
	Appendix D:	  	Designated Contact Persons and Key Service Provider Personnel
	Appendix E:	  	Transfer of Designated Responsibilities (if any)

  
 [*] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 19 of 22

 APPENDIX C 
 SAMPLE CHANGE ORDER 
 CHANGE ORDER NO.     FOR WORK
ORDER NO.      
 This Change Order No.      to Work Order No.      is by and
between Portola Pharmaceuticals, Inc. (“Portola”) and [*] (the “Service Provider”), and upon execution will be incorporated into Work Order No.      and the Master Contract Services
Agreement between Portola and Service Provider dated [*] (the “Agreement”). All capitalized terms used in this Change Order shall have the meaning set forth in the Agreement. Portola and Service Provider agree that Work Order No.
     is hereby revised as follows: 
 [*] 

 

	 	9.1	This Change Order is subject to the terms and conditions of the Agreement and Work Order No.     . In the event of a conflict between the
terms of this Change Order and the Agreement, the terms of the Agreement shall govern. The effective date of this Change Order is the date of the last signature below. [*] 

 

									
	CHANGE ORDER AGREED TO AND ACCEPTED BY:	 		 	
			
	PORTOLA PHARMACEUTICALS, INC.	 		 	[*]
					
	By	 	  
	 		 	By	 	  

					
	Print Name	 	  
	 		 	Print Name	 	  

					
	Title	 	  
	 		 	Title	 	  

		 	duly authorized	 		 		 	duly authorized
					
	Date	 	  
	 		 	Date	 	  

  
 [*] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 20 of 22

 APPENDIX D 

 

	1.	Currency Management. 

  

	 	a)	Direct Fees: All Direct Fees owed to CRO for Services performed under this Agreement or any Schedule shall generally be invoiced to and paid by Portola in $ USD
for Services performed in the North America (NA), Latin America (LA) and Asia-Pacific (APAC) regions and invoiced to and paid by Portola in € Euros for Services performed in Europe, the Middle East and Africa (EMEA); the “Regional Contract
Currency/Currencies”. 

 Should Portola wish to be invoiced in $ USD for Services performed in EMEA, CRO shall
specify in the proposal and the contract the estimated exchange rate (“Exchange Rate”) used to prepare the budget or payment schedule for such Project Addendum. This Exchange Rate will be the one used for the preparation of
each invoice for Services and payment by Portola. The “Spot Rate” for purposes of reconciliation, shall mean the actual spot rate in the Wall Street Journal at the close of the day before the date on which the invoice is raised. At the
conclusion of each calendar year, a reconciliation shall be undertaken. 
 If requested by Portola, CRO shall compare the USD
total of the invoices billed to Portola that year at the Exchange Rate with the USD total of those same invoices when converted using the Spot Rate. In the event the comparison demonstrates that the difference in such amounts is [*] or more or is
greater than USD $[*] such difference shall be [*] with the difference invoiced or credited, as the case may be, to Portola (an example of which follows below). The reconciliation invoice or credit note will be issued by CRO in $ USD. The process of
reconciliation is not cumulative but shall be conducted on a calendar year basis and completed by the end of March in the subsequent year. 
 Shared Reconciliation Examples: 
  

	 	•	 	 FX Variance is $[*] representing [*] of the total FX component of the annual invoicing: 

 

	 	•	 	 An adjustment (cash) is made between Portola and CRO for $[*] being the excess of the variance over $[*] ($[*] for $[*])

  

	 	•	 	 FX Variance is $[*] representing [*] of the total FX component of the annual invoicing: 

 

	 	•	 	 An adjustment (cash) is made between Portola and CRO for $[*] being the excess of the variance over [*] ($[*] for $[*])

  

	 	•	 	 FX Variance is $[*] representing [*] of the total FX component of the annual invoicing: 

 

	 	•	 	 No adjustment is required 

  

	 	b)	Pass Through Costs: Where CRO incurs Pass Through Costs in a currency other than $ USD in NA, LA or APAC and other than € Euros in EMEA, the Regional
Contract Currency/Currencies, CRO shall, for Portola invoicing and payment purposes, convert such costs to the applicable Regional Contract Currency based on an average exchange rate between the local currency and the regional Contract Currency for
the month in which such costs were incurred. 

  

	 	c)	Investigator Fees: CRO shall pay investigator fees in the currency specified in the investigator agreements. For Portola invoicing and payment purposes, CRO
shall convert all investigator fees that are to be paid in a currency other than the Regional Contract Currency to the Regional Contract Currency. The conversion to the Regional Contract Currency shall be based on an average exchange rate between
the currency specified in an investigator agreement and the Regional Contract Currency 

  
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

  
 Page 21 of 22

	 	
for the month prior to the month the Portola invoice is raised. All amounts invoiced to Portola will be based upon an accrual of costs owed to investigators. At the end of the project a
reconciliation will be completed between the estimated exchange rate used for the purposes of billing on the basis of the accrued costs versus the exchange rate when the actual payment is made to the sites, and any variation will be billed or
credited to Portola as applicable. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 22 of 22

			
	SERVICE PROVIDER:	  	 • PPD Development, LLC

	SERVICE PROVIDER CONTACT:	  	 • Julia Day

	MCSA EFFECTIVE DATE:	  	 • January 2, 2012

  
  

AMENDMENT NO. 1 TO 
 MASTER CONTRACT SERVICES AGREEMENT 
 FOR PRECLINICAL AND CLINICAL SERVICES

 THIS AMENDMENT NO. 1 (the “Amendment”) to the Master Contract Services Agreement (defined below) is made effective as of
March 5, 2012 by and between Portola Pharmaceuticals, Inc., (“Portola”) and PPD Development, LLC, (formerly PPD Development, LP, “Service Provider”) and upon execution will be incorporated into the Master Contract Services
Agreement for Preclinical and Clinical Services between Portola and Service Provider dated January 2, 2012 (the “Master Contract Services Agreement”). All capitalized terms not defined in this Amendment shall have the same meaning as
in the Master Contract Services Agreement. 
 WHEREAS, a Master Contract Services Agreement, effective January 2,
2012, was entered into by and between Portola and Service Provider; and 
 WHEREAS, the parties now wish to amend
Section 8.2 of the Master Contract Services Agreement. 
 NOW, THEREFORE, in consideration of the premises contained
herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
  

	 	1.	Indemnification by Portola. Section 8.2 of the Master Contract Services Agreement is hereby deleted in its entirety and replaced with the following:

 Portola agrees to indemnify Service Provider and its directors, officers, and employees and Service
Provider’s Affiliates authorized by Portola under a Power of Attorney, or similar instrument, to perform Services on behalf of Portola (collectively, the “Service Provider Indemnitees”) from and against any and all Losses they
may suffer in connection with any claim or lawsuit brought by a third party arising from (a) personal injury, or death of a Study subject caused by (i) any Study Drug or other materials supplied by Portola or anyone acting on
Portola’s behalf that is dispensed in strict accordance with the relevant Protocol and Portola’s written instructions, (ii) any non-standard of care procedure required by the Protocol, (b) any deviations from the applicable
Protocol necessary to preserve the health, safety and welfare of the Study subjects that meets all applicable standards of care, (c) any claims for patent infringement related to a Study Drug, compound or other materials supplied by Portola, or
anyone acting on Portola’s behalf, to Service Provider in connection with a Study, provided Service Provider Indemnitee has acted in strict compliance with the relevant Protocol and Portola’s instructions, (d) after regulatory
approval of a Study Drug that was the subject of the Services, personal injury or death caused by such Study Drug, or (e) a Portola Indemnitees’ use of the Deliverables, negligence, willful misconduct, or material breach of this Agreement.
Notwithstanding the foregoing, Portola’s obligation to indemnify the Service Provider Indemnitees will be proportionally reduced to the extent that such Losses fall within Service Provider’s indemnification obligations under
Section 8.1 above. 

  
 Page 1 of 2

 Except as expressly provided in this Amendment, the Master Contract Services Agreement remains unchanged and
in full force and effect. This Amendment may be executed in any number of counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. A facsimile or scanned copy of this Amendment
that includes a party’s signature will be deemed an original. 
 IN WITNESS WHEREOF, the parties have caused this
Amendment to be executed by their duly authorized representatives as of the Effective Date. 
  

									
	PORTOLA PHARMACEUTICALS, INC.	 		 	PPD DEVELOPMENT, LLC
					
	By:	 	 /s/ Mardi C. Dier
	 		 	By:	 	 /s/ William J. Sharbaugh

					
	Print Name:	 	 Mardi C. Dier
	 		 	Print Name:	 	 William J. Sharbaugh

					
	Title:	 	 Chief Financial Officer
	 		 	Title:	 	 Chief Operating Officer

					
	Date:	 	 3/21/12
	 		 	Date:	 	 3/9/2012

  
 [*] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]